The Life Sciences Virtual Investor Forum, co-hosted by Zacks Small-Cap Research and B2i Digital, will take place on June 24 and 25, 2026, featuring presentations from more than 20 publicly traded life sciences companies. The event provides investors with direct access to management teams through live presentations, real-time Q&A, and one-on-one meetings, according to a press release from B2i Digital.
The two-day lineup spans clinical-stage biotechnology, rare-disease and oncology therapeutics, molecular diagnostics, medical devices, veterinary medicine, nutrition science, and AI-powered digital health. Among the presenting companies are Protalix BioTherapeutics, CytoSorbents Corporation, Jaguar Health, 4DMedical, Prostatype Genomics, Abingdon Health, IMUNON, Envoy Medical, and Phio Pharmaceuticals, with schedules available on the event website.
Zacks Small-Cap Research, a preferred provider in the OTC Markets Group's Research Marketplace, brings independent company-sponsored research to the forum. Its team of life sciences analysts supports the event as co-host, adding credibility for investors seeking unbiased analysis. B2i Digital, as the Official Marketing Partner, amplifies the event across its platform, targeting a proprietary network of more than 1.7 million retail and institutional market participants. The same visibility engine has supported over 115 investor conferences.
Each company has 30 minutes for a live presentation and Q&A. One-on-one meeting requests are available through the VIC site, with replays available on B2i Digital and OTC Markets YouTube channels. Registration and company profiles can be accessed via the Virtual Investor Conferences website: https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/149532/june-24th-25th-life-sciences-virtual-investor-forum.
“Life sciences investors want efficient, direct access to management teams developing the therapies and technologies that matter, and pairing that access with independent research from Zacks makes the forum more valuable on both sides,” said David Shapiro, Chief Executive Officer of B2i Digital. The event reflects a growing trend of virtual investor conferences that lower barriers for smaller public companies to reach a broad investor base.
The forum holds significance for investors seeking early-stage opportunities in life sciences, particularly in therapeutic areas with high unmet need. The inclusion of Zacks Small-Cap Research provides an additional layer of due diligence, as the firm prepares independent analysis that can help investors evaluate companies. B2i Digital's marketing engine ensures that presentations reach a wide audience, potentially increasing liquidity and visibility for participating firms.
Virtual Investor Conferences, an OTC Markets Group property, features public companies from exchanges worldwide, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and OTC Markets. The event underscores the continued shift toward digital investor relations, offering cost-effective access for both companies and investors. For more details on B2i Digital's role, visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum.
